

CURRENT TOPIC / AKTUELNA TEMA

An anesthesiologist's perspective on advancements in perioperative analgesia

Dragana Milivojević¹, Aleksandra Obreški¹, Tjaša Ivošević¹, Katarina Savić Vujović², Ana Jotić^{3,4}¹University Clinical Center of Serbia, Center for Anesthesia and Resuscitation, Belgrade, Serbia;²University of Belgrade, Faculty of Medicine, Institute of Pharmacology, Toxicology and Clinical Pharmacology, Belgrade, Serbia;³University of Belgrade, Faculty of Medicine, Belgrade, Serbia;⁴University Clinical Center of Serbia, Clinic for Otorhinolaryngology and Maxillofacial Surgery, Belgrade, Serbia**SUMMARY**

Introduction Effective perioperative pain management remains a cornerstone of modern anesthesiology, directly influencing patient outcomes, recovery times, and overall satisfaction. This paper aims to explore advancements in perioperative analgesia, focusing on updated guidelines, innovative strategies for pain management, and the role of multimodal anesthesia in optimizing outcomes. The paper highlights the anesthesiologist's pivotal role in implementing these strategies while addressing challenges such as opioid overuse and inadequate pain control.

Methods A comprehensive study was conducted, analyzing recent studies, clinical trials, and guideline updates published over the past decade. The paper examines the evolution of multimodal anesthesia, which integrates non-opioid analgesics, regional techniques, and non-pharmacologic interventions to reduce opioid reliance and enhance recovery. Special attention is given to the management of pain in vulnerable populations, including pediatric and geriatric patients, and those with chronic conditions.

Results Findings reveal that adherence to evidence-based guidelines, combined with a multimodal approach, significantly improves pain management and patient outcomes. Recent innovations, including the use of enhanced recovery after surgery protocols, perioperative nerve blocks, and adjunct therapies such as ketamine and gabapentinoids, are reshaping clinical practice. The paper also emphasizes the importance of personalized pain management plans and continuous education for anesthesiologists.

Conclusion This paper concludes that the integration of updated guidelines, multimodal strategies, and patient-centric care models is essential for achieving optimal analgesic outcomes. Future research should focus on refining multimodal protocols, exploring novel analgesics, and addressing barriers to implementation in diverse clinical settings.

Keywords: perioperative analgesia; multimodal anesthesia; enhanced recovery after surgery

INTRODUCTION

Effective perioperative pain management is a critical aspect of modern anesthesia. Poorly controlled pain during and after surgery not only delays recovery but can also lead to short- and long-term complications, including chronic post-surgical pain (CPSP) and opioid dependency [1]. Current clinical practice often relies heavily on opioids as the cornerstone of analgesia, despite the well-documented risks of opioid-related side effects, including respiratory depression, nausea, and the potential for long-term dependency. Pain management remains inconsistent across different health-care settings, with significant variability in the adoption of multimodal analgesic strategies and adherence to evidence-based guidelines [2].

New guidelines and research emphasize the need for multimodal anesthesia (MMA) – an approach that combines various analgesic techniques and pharmacologic agents that act synergistically to target different pain pathways and reduce the reliance on any single drug, particularly opioids. Techniques such as regional

anesthesia and the use of adjunctive medications (e.g., ketamine, dexmedetomidine, and gabapentinoids) are gaining interest in the last decade. The integration of these strategies into routine clinical practice is still slow, due to lack of training, resource constraints, and variability in institutional protocols [1].

The aim of this review is to address updates to guidelines, novel perioperative pain management strategies, and the role of MMA in optimizing surgery outcomes, as well as improving and enhancing patient-centered care.

METHODS

Literature search was conducted using PubMed, MEDLINE, and Google Scholar database for published articles in the past 30 years (1995–2025). Terms used in the search were “perioperative analgesia,” “multimodal analgesia,” “MMA,” “enhanced recovery after surgery,” “ERAS,” “perioperative pain,” “multimodal anesthesia,” “anesthesia.” Further articles were found through cross-referencing. Only articles

Received • Примљено:

May 29, 2025

Revised • Ревизија:

August 25, 2025

Accepted • Прихваћено:

September 9, 2025

Online first: September 15, 2025**Correspondence to:**

Ana JOTIĆ
University Clinical Center of Serbia
Clinic for Otorhinolaryngology
and Maxillofacial Surgery
Pasterova 2
1100 Belgrade
Serbia
anajotic@yahoo.com

that included human studies and were published in English were included in the review. Primary studies (e.g., retrospective studies, prospective studies, observational studies, randomized controlled trials, etc.), basic science research, metaanalyses, and systematic reviews were included, while case reports were excluded from the review.

Current challenges in pain management

Reliance on opioids as the primary analgesic has contributed to the opioid crisis, indicating a need for safer, multimodal approaches. Perioperative pain management is particularly challenging in special populations, such as elderly patients, pediatric patients, and individuals with significant comorbidities. A change in clinical practice is required, which focuses on individualized, evidence-based strategies that decrease opioid use, but still offer efficient analgesia.

Inadequate perioperative pain control

Perioperative pain control remains inadequate, despite advances in anesthetic techniques and pain management protocols. Many surgical patients continue to experience moderate to severe postoperative pain. Poorly managed pain can lead to immediate postoperative complications, prolonged hospital stays, and even long-term health consequences such as CPSP [3].

CPSP is defined as pain persisting beyond three months after surgery and affects approximately 10–50% of patients, depending on the surgical procedure [4]. Surgeries with the highest CPSP incidence include thoracotomy, mastectomy, total knee arthroplasty, hernia repair, and amputation. Risk factors for CPSP include poorly controlled acute pain, repeated surgical trauma, nerve damage, psychological stress, and pre-existing chronic pain conditions. Effective perioperative pain management, particularly through regional anesthesia and multimodal analgesia, can significantly reduce the risk of CPSP [4].

Severe postoperative pain can lead delayed recovery and increased morbidity, including the risk of deep vein thrombosis (DVT), pulmonary embolism, pneumonia, and muscle deconditioning. Inadequate analgesia prolongs hospital stays and increases the likelihood of unplanned readmissions, raising healthcare costs. Poorly controlled pain can impair gastrointestinal function, leading to postoperative ileus, nausea, and vomiting, further delaying recovery [5]. It can also have significant psychological and emotional impact, contributing to postoperative anxiety, depression, and sleep disturbances [6].

Opioid use and associated risks

Opioids have traditionally been the cornerstone of perioperative pain management due to their potent analgesic effects. Overreliance on opioids and their widespread use has led to a host of complications, including dependency, addiction, and a growing healthcare burden. Studies indicate that 5–10% of opioid-naïve patients who receive

opioids postoperatively develop long-term dependence [7]. A significant proportion of opioid-related deaths stem from prescriptions initially provided for postoperative pain management [8]. Adverse effects of opioids include acute opioid tolerance, iatrogenic withdrawal syndrome, persistent opioid use, chronic pain, and opioid-induced hyperalgesia [9].

MMA PROTOCOL IN PAIN MANAGEMENT

Pharmacological combinations of analgesics and non-pharmacological therapies and minimize opioid use are the fundamental components of MMA protocol. Adjuvant therapies should be administered before surgery to optimize intraoperative and postoperative analgesia, to reduce opioid-related adverse effects in the recovery period [10].

Multimodal approach is more focused on non-opioid analgesics (nonsteroidal anti-inflammatories, acetaminophen, gabapentinoids, N-methyl D-aspartate (NMDA) antagonists, alpha-2-agonists), regional anesthesia techniques, and non-pharmacological strategies to decrease the use of opioids and associated side effects [10]. It may be more effective as a pain control strategy, decreasing the complications associated with suboptimal pain control, such as pneumonia, DVT, and postoperative cognitive dysfunction. Nevertheless, opioids still have a critical role in acute postoperative pain management especially for procedures where a primary regional, neuraxial, or local infiltration is not possible [11].

Acetaminophen remains the recommended first-line treatment for mild-to-moderate acute pain in general population, especially in vulnerable populations. It can be used in combination with non-steroidal anti-inflammatory drugs (NSAIDs) with synergistic effect, which is desirable in multimodal protocols for optimal pain control [12]. There is evidence that acetaminophen achieves analgesic effect through multiple pathways. One mechanism of action is through cyclooxygenase (COX)-dependent inhibitory effect and by the formation of the bioactive AM404 metabolite as a potent activator of transient receptor potential vanilloid 1, a major contributor to neuronal response to pain in the brain and dorsal horn. Acetaminophen also decreases central oxidative stress and prostaglandin release, which effects descending pain inhibitory pathways. The side effects are generally mild and include nausea, headache, stomach pain, and a rash, while the most serious side effect is liver toxicity which does not occur unless taken in large quantities [13].

NSAIDs reduce pain by reducing the activity of cyclooxygenase (or COX) enzymes and inhibiting peripheral prostaglandin synthesis. Non-selective NSAIDs such as ibuprofen, diclofenac, and naproxen inhibit both COX-1 and COX-2 enzymes. Selective NSAIDs (COX-2 inhibitors, coxibs) such as celecoxib and etoricoxib selectively inhibit COX-2, which plays a greater role in prostaglandin mediated pain and inflammation [14]. NSAIDs are routinely used in perioperative and postoperative analgesia, as opioid-sparing analgesics, for treatment moderate to severe

Table 1. Non-opioid analgesics used in multimodal approach of pain control

Analgesics	Analgesic Mechanism of action	Application	Dosage	Adverse effects
Acetaminophen	• Inhibiting COX-1 and COX-2 enzymes • Activating the TRPV1 and CB-1	Oral, rectal, and intravenous route	• In children > 12 years and adults 500–1000mg every 4–6 hours (maximum 4000 mg daily) • In children one month to 12 years 15 mg/kg per dose every six hours	• Potentiate warfarin anticoagulation • Chronic alcohol misuse increases the risk of toxicity • Contraindicated in cases of active liver disease or severe hepatic impairment. • Other: skin rash, hypersensitivity reactions, nephrotoxicity
NSAIDs	• Non selective inhibition of both COX-1 and COX-2 or selective inhibition of COX-2	Oral, intramuscular, and intravenous route	Diclofenac: 50–75mg mg 2–3 times/daily or (max 150 mg) PO or IM. Ibuprofen: Initial dose 400 mg IV, then 100–200 mg 4–6 hours IV 1200–3200m/daily in 3–4 doses PO Ketorolac: 15–30 mg every 4–6 hours IM or IV or 10 mg 4–6 hours PO Meloxicam: 7.5–15 mg daily PO Celecoxib: 50–200 mg (daily in one or two doses PO	• Prolonged use can lead to gastric, renal and cardiovascular adverse effects • Hepatic adverse effects are less common • Possible hematologic adverse effects in hemophilia, thrombocytopenia, von Willebrand, etc.) • Other: anaphylactoid reactions that involve urticaria and aspirin-exacerbated respiratory disease.
Gabapentinoids	• Inhibition of calcium-mediated neurotransmitter release through effects on $\alpha 2\delta$-1 subunits	Oral route	Gabapentine: 900–3600 mg/day in three doses PO Pregabalin: 150–600 mg/day in two to three doses PO	• CNS adverse effects (dizziness, senescence, gait disturbances) • Gastrointestinal adverse effects (abdominal distension, abnormal appetite, constipation, dry mouth and nausea) • Weight gain • Respiratory depression when used in combination with opioids
NMDA antagonist (ketamine)	• NMDA and glutamate receptor antagonist	Intranasal, intravenous intramuscular route	• 0.3–0.5 kg/kg IV bolus • 0.1–0.2 mg / kg / h IV infusion • 1 mg/kg intranasally	• Cardiovascular, gastrointestinal, respiratory, neurologic and psychiatric side effects • Coadministration with opioid analgesics, benzodiazepines, CNS depressants, and alcohol, may induce profound sedation, respiratory depression, coma, and potentially fatal outcomes. • Coadministration with sympathomimetic medications may increase sympathomimetic effects • Coadministration with theophylline or aminophylline could potentially reduce the seizure threshold. • Contraindicated in patients with aortic dissection, uncontrolled hypertension, myocardial infarction, or aneurysms
Magnesium	• NMDA receptor antagonist	Oral, and intravenous route	Post-surgery: 30 mg/kg bolus followed by an infusion of 10 mg / kg / h Oral intake Children 2.5–5 mg/kg daily Adults 310–420 mg/daily	Contraindicated in renal dysfunction, pregnancy, and neuromuscular disease. Hypermagnesemia (levels greater than 2.6 mg/dL and above) can lead to cardiovascular complications, neurological disorder, cardiorespiratory arrest (serum values exceeding 15 mg/dL)
Alpha-2 agonists	• Agonist of presynaptic and postsynaptic α_2-adrenergic receptors nociceptive	Oral, IV, transdermal, epidural, perineural	Clonidine Oral premed: 2–4 μ g/kg; IV bolus: 1–2 μ g/kg; Epidural: 150–300 μ g Dexmedetomidine IV bolus: 0.5–1 μ g/kg over 10 min Infusion: 0.2–0.7 μ g/kg/h	Hypotension, bradycardia, sedation, dry mouth Contraindicated in severe bradyarrhythmia, hemodynamic instability, severe ventricular dysfunction, uncontrolled cerebrovascular disease
Intravenous lidocaine	• Inhibition of VGSCs inhibition of G protein-coupled receptors • Inhibition of NMDA receptors	Intravenous route	1.5 mg/kg IV bolus 1–2 mg / kg / h IV infusion	Cardiovascular (bradycardia, hypotension) and neurological side effects (dizziness, seizures)

COX – cyclooxygenase; TRPV – transient receptor potential vanilloid; CB – cannabinoid; IM – intramuscular; IV – intravenously; PO – per os; NMDA – N-methyl-D-aspartate; CNS – central nervous system; VGSC – voltage-gated sodium channel

pain in children and adults. Regarding adverse effects and safety of NSAIDs, most patients are not at any increased risk of developing adverse central, gastrointestinal, renal and respiratory adverse events. The recent introduction of celecoxib, a selective COX-2 inhibitor, has significantly decreased the risk of postoperative gastrointestinal bleeding and anastomotic leak that are traditionally associated with non-selective NSAIDs. Despite their overall favorable safety profile, NSAIDs should be used with caution in patients with non-erosive reflux disease, patients with prior myocardial infarction on antithrombotic therapy, patients with asthma, and patients with a history of renal disease [15].

Gabapentinoids (gabapentin and pregabalin) are antiepileptic agents which can be used as perioperative analgesics. Mechanism of actions involves inhibition of presynaptic calcium-mediated neurotransmitter release through effects on $\alpha_2\delta$ -1 subunits in the dorsal root ganglia and spinal cord which are upregulated in the event of surgical trauma, resulting in non-distribution excitatory neurotransmitters [16]. Gabapentinoids are effective in gynecologic, breast, orthopedic, and spine surgery, when administered two hours before surgery in smaller doses due to concern for respiratory depression [17].

NMDA antagonist. Ketamine has been shown to effectively alleviate pain as antagonists of central NMDA receptors. Its effects are dose dependent: at anesthetic doses it produces dissociative anesthesia, whereas at sub-anesthetic doses (typically 0.25–0.5 mg/kg bolus followed by 0.1–0.3 mg/kg/h infusion) it exerts strong analgesic and anti-hyperalgesic effect without loss of consciousness [18]. The most common adverse events associated with ketamine/s-ketamine are dissociation, anxiety, nausea, increased blood pressure, and headache. Most side effects are mild, transient, dose dependent, and attenuate with subsequent treatments. When compared to ketamine, use of subanesthetic S-ketamine in MMA protocols is associated with fewer psychomimetic adverse effects, less emergence delirium, and overall better tolerability [19].

Magnesium is a NMDA receptor antagonist, causing central nervous system (CNS) depression through calcium channels. Magnesium has analgesic effect, reduces postoperative pain and opioid consumption in surgical patients and can be successfully used as a part of multimodal perioperative analgesia [20].

Alpha-2 agonists (clonidine, dexmedetomidine) are often used perioperatively to enhance analgesia, stabilize hemodynamics, and reduce opioid consumption [2]. They act as antagonists of presynaptic and postsynaptic α_2 -adrenergic receptors in the CNS, leading to inhibition of norepinephrine release, decreased sympathetic outflow, and modulation of spinal and supraspinal nociceptive transmission. This results in sedative, anxiolytic, and analgesic effects, along with an opioid-sparing action valuable in perioperative pain management [11]. Adverse effects are generally dose dependent and include bradycardia, hypotension, sedation, and, less frequently, dry mouth and delayed recovery if overdosed.

Intravenous local anesthetics (lidocaine). These medications are currently not routinely used for perioperative

pain control, because of limited evidence available in the literature [13]. There are data that indicate that lidocaine infusions reduce postoperative pain scores, nausea, and vomiting, and accelerate bowel function and reduce opioid consumption after abdominal surgery [21]. Lidocaine inhibits of sodium channels, G protein-coupled receptors, and NDMA receptors, leading to suppression of local and systemic inflammation, nociceptive transmission, and central sensitization. Side effects from perioperative intravenous lidocaine infusion include drowsiness and blunted response to tracheal extubation, as well as symptoms commonly associated with local anesthetic systemic toxicity such as tinnitus, perioral numbness, lightheadedness, dizziness, visual changes, and more seriously arrhythmias and seizures [22].

REGIONAL AND LOCAL ANESTHESIA TECHNIQUES

Regional anesthesia includes both neuraxial (spinal and epidural) anesthesia and peripheral nerve blocks. These techniques have resulted in better control of perioperative pain, decreased opioid use and time spent in the post-anesthesia care unit after various surgical procedures [23]. There is evidence that show that application of regional anesthesia can prevent persistent postoperative pain and chronic postsurgical pain in postoperative settings. Regional anesthesia techniques carry a certain risk of complications like nerve injury, bleeding, infection, rebound pain, and potential local anesthetic toxicity. In the last decade, use of ultrasound guidance has mostly contributed to wider use and the safety of regional anesthesia, resulting in reducing these complications in clinical settings [24].

Traditionally, bupivacaine was mostly used in regional anesthesia. Levobupivacaine and ropivacaine were developed as isomers with nearly identical effects in onset, quality, and duration of sensory block, but better safety profile comparing to bupivacaine [24]. For better pain management, both proved to be effective in combination with fentanyl [23].

Epidural anesthesia and spinal anesthesia are one of the oldest forms of regional anesthesia. They are often used in thoracic surgery, orthopedic surgery, and obstetrical procedures. The paravertebral block involves the delivery of local anesthetics to the paravertebral space near the spinal nerves emerging from the intervertebral foramen which is a reliable technique for reducing pain in the immediate postoperative period after breast surgery. Upper limb nerve blocks are employed due to the high incidence of postoperative pain in upper limb surgeries. The transverse abdominis plane block involves application of local anesthetics to the fascial plane between the internal oblique and transverse abdominus muscles and it is used for colorectal surgeries and obstetrical procedures. Quadratus lumborum block involves application of local anesthetic around the quadratus lumborum muscle and covers which is effective for abdominal, obstetric, pelvic, and renal surgeries. Erector spinae block is a fascial plane technique used to treat both acute and chronic pain, with many applications

ranging from head and neck, thoracic, abdominal, and lower extremity surgical procedures. These techniques are considered safe, result in excellent perioperative analgesia and decrease use of opioids postoperatively [25].

One major drawback of regional anesthesia is its limited duration of effective analgesia. This depends on the type, volume, concentration of applied local anesthetic, and patients' comorbidities, but could result in intense postoperative pain and rebound pain. These effects can be more easily managed for patients in hospital settings, than for those who had one-day surgery which usually require for post-discharge medical attention. As a result of efforts to increase the length of analgesia in pre-existing local anesthetics led to development of new formulations of local anesthetics like EXPAREL® (Pacira BioSciences, Inc., Brisbane, CA, USA) liposomal bupivacaine and SABER®-Bupivacaine (DURECT Corp., Cupertino, CA, USA). These medications have significantly reduced postoperative pain levels up to 72 hours, opioid consumption and hospital stay, while increasing the time to first rescue opioid medication use [23].

ROLE OF MMA PROTOCOL IN ENHANCED RECOVERY AFTER SURGERY (ERAS)

ERAS protocols are multimodal perioperative care pathways designed to achieve fast recovery in patients after surgical procedures by defining and maintaining preoperative organ function and minimizing the stress response following surgery. Unlike traditional perioperative management, which often focuses on isolated interventions, ERAS integrates multimodal protocols across various perioperative stages to create multidisciplinary, evidence-based approach designed to improve surgical outcomes, minimize reliance on opioids while enhancing pain control and reduce postoperative complications by optimizing perioperative care [11].

A multi-society consensus statement [26] establishes seven guiding principles for acute perioperative pain management to help institutions enhance surgical patient care. These principles emphasize the need for preoperative evaluation of medical and psychological conditions, screening for potential substance use disorders, a focus on multimodal analgesia incorporating nonpharmacologic interventions, and the use of validated pain assessment tools to guide and adjust treatment. The consensus highlights that clinicians should conduct a thorough preoperative evaluation, assessing medical and psychological conditions, medication history, chronic pain, substance use disorder, and prior postoperative pain treatment responses to develop a personalized pain management plan [11].

Preoperative phase in ERAS protocol involves comprehensive preoperative preparation, where MMA plays a vital role in effective perioperative analgesia. Psychological preparation of patients, including cognitive behavioral strategies and anxiety reduction techniques, minimizes the stress response to surgery. Preoperative counseling also addresses expectations regarding postoperative pain control and early mobilization [24]. Preemptive administration of

non-opioid analgesics, such as acetaminophen or NSAIDs, is an essential part of ERAS. Preoperative carbohydrate loading reduces insulin resistance and enhances metabolic recovery, indirectly contributing to improved analgesia and reduced catabolism [24]. Patients at risk of chronic pain or opioid use disorder may receive gabapentinoids or NMDA receptor antagonists as part of a preemptive multimodal approach [16].

The intraoperative phase of ERAS focuses on maintaining hemodynamic stability, minimizing surgical stress, and ensuring effective analgesia while avoiding excessive sedation or opioid burden. MMA within ERAS emphasizes a balance between analgesia and hemodynamic stability. Planned application of fluid therapy prevents fluid overload, which reduces tissue edema, optimizes oxygen delivery, and enhances postoperative recovery. Maintaining normothermia through warming devices reduces surgical stress and supports hemodynamic stability [26]. A balanced anesthesia approach prioritizes opioid-sparing approach prioritize integration of regional techniques and patient-specific sedation. Total intravenous anesthesia with added dexmedetomidine or lidocaine may improve postoperative pain control while avoiding opioid-related side effects such as nausea and ileus [11]. The use of short-acting anesthetic agents facilitates early emergence and immediate postoperative recovery. Suppressing the surgical stress response using multimodal strategies reduces postoperative catabolism, immune dysfunction, and pain hypersensitivity. Techniques such as regional blocks or neuraxial anesthesia mitigate the neuroendocrine stress response to surgery. Anti-inflammatory agents, such as corticosteroids, further enhance recovery by modulating the surgical inflammatory response [14].

The postoperative phase of ERAS focuses on optimizing analgesia to supports rapid emergence and allow patients to regain consciousness and protective airway reflexes faster. Avoiding long-acting opioids and benzodiazepines facilitates early extubation, reducing the risk of respiratory complications and postoperative delirium [26]. Multimodal analgesia also minimizes postoperative shivering, nausea, and excessive sedation, improving time spent in post-anesthesia care unit. It facilitates early return of bowel function and early oral intake [10]. Early mobility accelerates muscle recovery, shortens hospital length of stay, and decreases the incidence of postoperative complications such as pneumonia and DVT [11].

FUTURE DIRECTIONS AND IMPLEMENTATION OF MULTIMODAL APPROACHES IN SERBIA

The adoption of multimodal analgesia in perioperative protocols in Serbia faces several clinical challenges, although studies were already published on the subject [27]. One of the primary concerns is the existing training gap among anesthesiologists and surgical teams. Despite the evident benefits of multimodal analgesia, many healthcare professionals lack adequate exposure and hands-on experience in administering regional anesthesia techniques

effectively. Additionally, resistance to change among medical practitioners remains a significant obstacle. Many anesthesiologists and surgeons continue to rely on conventional management strategies due to familiarity and institutional inertia. Another critical challenge is the variability in hospital protocols across different healthcare institutions. While some hospitals have adopted comprehensive multimodal analgesia protocols, others continue to follow outdated pain management strategies, leading to inconsistent patient outcomes [28].

Limited access to resources slows down implementation of multimodal analgesia in Serbia. The availability of regional anesthesia techniques and multimodal drug combinations is inconsistent across hospitals, particularly in smaller healthcare facilities. To overcome these challenges, primary goal should be establishing structured educational programs that focus on multimodal analgesia. These programs should be integrated into anesthesiology training curricula and include hands-on workshops to ensure competency in regional anesthesia techniques. Efforts should be made to promote adherence to national and international guidelines and standardize perioperative pain management protocols across healthcare institutions. Interdisciplinary collaboration between anesthesiologists, surgeons, and pain specialists is essential for the successful adoption of multimodal analgesia. Establishing acute pain service units in hospitals can also facilitate coordinated pain management efforts and ensure optimal patient care [29].

REFERENCES

- Schug SA, Palmer GM, Scott DA, Alcock M, Halliwell R, Mott JF; APM:SE working group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence. 5th ed. Melbourne: ANZCA & FPM; 2020.
- O'Neill A, Lirk P. Multimodal analgesia. *Anesthesiol Clin*. 2022;40(3):455–68. [DOI: 10.1016/j.anclin.2022.04.002] [PMID: 36049874]
- Liu Y, Xiao S, Yang H, Lv X, Hou A, Ma Y, et al.; CAPOPS Group. Postoperative pain-related outcomes and perioperative pain management in China: a population-based study. *Lancet Reg Health West Pac*. 2023;39:100822. [DOI: 10.1016/j.lanwpc.2023.100822] [PMID: 37927993]
- Rosenberger DC, Pogatzki-Zahn EM. Chronic post-surgical pain – update on incidence, risk factors and preventive treatment options. *BJA Educ*. 2022;22(5):190–6. [DOI: 10.1016/j.bjae.2021.11.008] [PMID: 35496645]
- Liu QR, Dai YC, Ji MH, Liu PM, Dong YY, Yang JJ. Risk Factors for Acute Postsurgical Pain: A Narrative Review. *J Pain Res*. 2024;17:1793–804. [DOI: 10.2147/JPR.S462112] [PMID: 38799277]
- Moussa N, Ogle OE. Acute pain management. *Oral Maxillofac Surg Clin North Am*. 2022;34(1):35–47. [DOI: 10.1016/j.coms.2021.08.014] [PMID: 34750009]
- Barth RJ, Waljee JF. Classification of opioid dependence, abuse, or overdose in opioid-naïve patients as a “never event”. *JAMA Surg*. 2020;155(7):543–4. [DOI: 10.1001/jamasurg.2020.0432] [PMID: 32347906]
- United Nations Office on Drugs and Crime (UNODC). World Drug Report 2023 [Internet]. Vienna: UNODC; 2023 [cited 2025 Apr 26]. Available from: <https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html>
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain – United States, 2022. *MMWR Recomm Rep*. 2022;71(3):1–95. [DOI: 10.15585/mmwr.r7103a1] [PMID: 36327391]
- Joshi GP. Rational multimodal analgesia for perioperative pain management. *Curr Pain Headache Rep*. 2023;27(8):227–37. [DOI: 10.1007/s11916-023-01137-y] [PMID: 37405552]
- Mariano ER, Dickerson DM, Szokol JW, Harned M, Mueller JT, Philip BK, et al. A multisociety organizational consensus process to define guiding principles for acute perioperative pain management. *Reg Anesth Pain Med*. 2022;47(2):118–27. [DOI: 10.1136/rapm-2021-103083] [PMID: 34552003]
- Mallet C, Desmeules J, Pegahi R, Eschalié A. An updated review on the metabolite (AM404)-mediated central mechanism of action of paracetamol (acetaminophen): experimental evidence and potential clinical impact. *J Pain Res*. 2023;16:1081–94. [DOI: 10.2147/JPR.S393809] [PMID: 37016715]
- Hong B, Chung W, Oh C. Balancing benefit and risk: clinical considerations in the use of acetaminophen, non-steroidal anti-inflammatory drugs, and dexamethasone for perioperative multimodal analgesia. *Korean J Pain*. 2025;38(4):364–77. [DOI: 10.3344/kjp.25068] [PMID: 40527754]
- Hyland SJ, Brockhaus KK, Vincent WR, Spence NZ, Lucki MM, Howkins MJ, et al. Perioperative pain management and opioid stewardship: a practical guide. *Healthcare (Basel)*. 2021;9(3):333. [DOI: 10.3390/healthcare9030333] [PMID: 33809571]
- Arfeen M, Srivastava A, Srivastava N, Khan RA, Almahmoud SA, Mohammed HA. Design, classification, and adverse effects of NSAIDs: A review on recent advancements. *Bioorg Med Chem*. 2024;112:117899. [DOI: 10.1016/j.bmc.2024.117899] [PMID: 39217686]
- Williams CD, Al-Jammali Z, Herink MC. Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval. *Drugs*. 2023;83(1):37–53. [DOI: 10.1007/s40265-022-01810-3] [PMID: 36529848]
- Varadi G. Mechanism of analgesia by gabapentinoid drugs: involvement of modulation of synaptogenesis and trafficking of glutamate-gated ion channels. *J Pharmacol Exp Ther*. 2024;388(1):121–33. [DOI: 10.1124/jpet.123.001669] [PMID: 37918854]

CONCLUSION

Advancements in perioperative analgesia like importance of MMA, adherence to evolving guidelines, and a personalized approach have significantly transformed pain management and improve patient recovery and satisfaction. By integrating opioid-sparing techniques and regional anesthesia, anesthesiologists can optimize pain control while minimizing adverse effects. Recognizing the variability in patient responses emphasize the need for a personalized approach, where treatment is adapted to factors such as surgical type, comorbidities, and patient preferences. Anesthesiologists and healthcare providers must remain committed to continuous learning and guideline adherence to ensure optimal patient outcomes. Institutional policies should support the widespread implementation of evidence-based analgesic protocols, promoting interdisciplinary collaboration in perioperative care. By prioritizing these efforts, the medical community can continue to advance perioperative analgesia and improving patient safety and quality of life.

Ethics: The authors hereby declare that this article was prepared in full compliance with the ethical standards set forth by the journal Serbian Archives of Medicine, as well as the ethical guidelines and institutional policies adhered to by each author involved in the research and writing process.

Conflict of interest: None declared.

18. Savić Vujović K, Jotić A, Medić B, Srebro D, Vujović A, Žujović J, et al. Ketamine, an old-new drug: uses and abuses. *Pharmaceuticals (Basel)*. 2023;17(1):16. [DOI: 10.3390/ph17010016] [PMID: 38276001]
19. Ceban F, Rosenblatt JD, Kratiuk K, Lee Y, Rodrigues NB, Gill H, et al. Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. *CNS Drugs*. 2021;35(9):925–34. [DOI: 10.1007/s40263-021-00846-5] [PMID: 34363603]
20. Morel V, Pickering ME, Goubayon J, Djobo M, Macian N, Pickering G. Magnesium for Pain Treatment in 2021? State of the Art. *Nutrients*. 2021;13(5):1397. [DOI: 10.3390/nu13051397] [PMID: 33919346]
21. Weibel S, Jeltung Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. *Cochrane Database Syst Rev*. 2018;6(6):CD009642. [DOI: 10.1002/14651858.CD009642] [PMID: 29864216]
22. Ghimire A, Subedi A, Bhattarai B, Sah BP. The effect of intraoperative lidocaine infusion on opioid consumption and pain after totally extraperitoneal laparoscopic inguinal hernioplasty: a randomized controlled trial. *BMC Anesth*. 2020;20(1):137. [DOI: 10.1186/s12871-020-01054-2] [PMID: 32493276]
23. Regional Anesthesia and Acute Pain Medicine: A Problem-Based Learning Approach. USA: Oxford University Press; 2023.
24. Chen Q, Chen E, Qian X. A narrative review on perioperative pain management strategies in enhanced recovery pathways-the past, present and future. *J Clin Med*. 2021;10(12):2568. [DOI: 10.3390/jcm10122568] [PMID: 34200695]
25. Simić D, Simić I, Stević M, Jović N, Mitrović M, Budić I, et al. The role of regional anesthesia in the postoperative analgesia in pediatric patients. *Srp Arh Celok Lek*. 2019;147(5–6):316–20. [DOI: 10.2298/SARH180116067S]
26. Dickerson DM, Mariano ER, Szokol JW, Harned M, Clark RM, Mueller JT, et al. Multiorganizational consensus to define guiding principles for perioperative pain management in patients with chronic pain, preoperative opioid tolerance, or substance use disorder. *Reg Anesth Pain Med*. 2024;49(10):716–24. [DOI: 10.1136/rapm-2023-104435] [PMID: 37185214]
27. Djukanović M, Skrobic O, Stojakov D, Knezević NN, Milčić B, Sabljak P, et al. Impact of fluid balance and opioid-sparing anesthesia within enhanced recovery pathway on postoperative morbidity after transthoracic esophagectomy for cancer. *Front Med (Lausanne)*. 2024;11:1366438. [DOI: 10.3389/fmed.2024.1366438] [PMID: 38770049]
28. Graham LA, Illarino SS, Wren SM, Odden MC, Mudumbai SC. Variations in Current Practice and Protocols of Intraoperative Multimodal Analgesia: A Cross-Sectional Study Within a Six-Hospital US Health Care System. *Anesth Analg*. 2024;141(4):847–55. [DOI: 10.1213/ANE.00000000000007299] [PMID: 39453849]
29. Dohlman LE, Kwiriza A, Ehie O. Benefits and barriers to increasing regional anesthesia in resource-limited settings. *Local Reg Anesth*. 2020;13:147–58. [DOI: 10.2147/LRA.S236550] [PMID: 33122941]

Перспектива анестезиолога о новинама на пољу периперативне аналгезије

Драгана Миливојевић¹, Александра Обрешки¹, Тјаша Ивошевић¹, Катарина Савић Вујовић², Ана Јотић^{3,4}

¹Универзитетски клинички центар Србије, Клиника за оториноларингологију и максилотофацијалну хирургију, Центар за анестезију и реанимацију, Београд, Србија;

²Универзитет у Београду, Медицински факултет, Институт за фармакологију, токсикологију и клиничку фармакологију, Београд, Србија;

³Универзитет у Београду, Медицински факултет, Београд, Србија;

⁴Универзитетски клинички центар Србије, Клиника за оториноларингологију и максилотофацијалну хирургију, Београд, Србија

САЖЕТАК

Увод Ефикасна периперативна терапија бола остаје основна модерне анестезиологије, јер директно утиче на исход оперативног лечења пацијената, време опоравка и укупно задовољство пацијената. Овај рад има за циљ да истражи новине у периперативној аналгезији, фокусирајући се на нове смернице и стратегије за терапију бола, као и улогу мултимодалне анестезије у оптимизацији исхода лечења. Битно је истаћи улогу анестезиолога у имплементацији ових стратегија, али и изазове у клиничкој пракси, као што су прекомерна употреба опиоида и неадекватна контрола бола.

Метод Сprovedено је свеобухватно истраживање које анализира најновије студије, клиничка испитивања и ажуриране смернице објављене током претходне деценије. Рад испитује еволуцију мултимодалне анестезије, која обједињује употребу неопиоидних аналгетика, регионалних техника и нефармаколошких интервенција како би се смањило ослањање на опиоиде и побољшао опоравак. Посебна пажња се посвећује управљању болом у угроженим популацијама, укључујући педијатријске и геријатријске пацијенте и оне са хроничним стањима.

Резултати Налази истраживања откривају да праћење смерница заснованих на доказима, у комбинацији са мултимодалним приступом, значајно побољшава терапију бола и исход оперативног лечења пацијената. Савремене иновације, укључујући спровођење протокола побољшаног опоравка после операције, употребу периперативних нервних блокова и помоћних лекова као што су кетамин и габапентиноиди, значајно мењају клиничку праксу. Овај рад наглашава и важност персонализованих планова за терапију бола и спровођења континуиране едукације за анестезиологе.

Закључак Треба нагласити да је интеграција нових смерница, мултимодалних стратегија и модела неге усмерених на пацијента од суштинског значаја за постизање оптималних исхода аналгезије. Будућа истраживања треба да се фокусирају на усавања мултимодалних протокола, истраживање нових аналгетика и решавање препрека за имплементацију ових метода у различитим клиничким окружењима.

Кључне речи: периперативна аналгезија; мултимодална анестезија; побољшан опоравак након операције